Exane Derivatives Alaunos Therapeutics, Inc. Transaction History

Exane Derivatives

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$0.41 - $1.24 $16,670 - $50,418	-40,660 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$0.62 - $1.17 $25,209 - $47,572	40,660 New	40,660 $26,000
Q3 2021 Oct 26, 2021	SELL	$1.44 - $2.73 $65,126 - $123,469	-45,227 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$2.82 - $5.6 $95,891 - $190,422	34,004 Added 302.98%	45,227 $162,000
Q4 2020 Jan 27, 2021	BUY	$2.09 - $3.09 $23,456 - $34,679	11,223 New	11,223 $28,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.